Autosomal dominant multiple pterygium syndrome
aw-toh-SOH-muhl DAH-muh-nuhnt MUL-tuh-puh-REE-jee-uhm SIN-drohm
Also known as: Escobar syndrome, Multiple pterygium syndrome, dominant type
At a Glance
What is Autosomal dominant multiple pterygium syndrome?
Autosomal dominant multiple pterygium syndrome is a rare genetic condition characterized by the presence of web-like skin folds called pterygia. These pterygia can occur in various parts of the body, including the neck, elbows, and knees, affecting movement and flexibility. The condition is caused by mutations in the MYH3 gene, which plays a role in muscle development. Symptoms can be present at birth and may include joint contractures, scoliosis, and facial anomalies. As individuals age, the severity of symptoms can vary, with some experiencing more pronounced physical limitations. Early diagnosis is crucial to manage symptoms and improve quality of life through physical therapy and surgical interventions. The condition can have a significant impact on family life, as it may require ongoing medical care and support. Prognosis varies depending on the severity of symptoms, but many individuals can lead fulfilling lives with appropriate management. Daily life for those affected may involve adapting to physical limitations and utilizing assistive devices. Family members may also need genetic counseling to understand inheritance patterns and risks for future pregnancies. Despite challenges, individuals with the condition can achieve personal and professional goals with support. Awareness and understanding of the condition can help reduce stigma and promote inclusion.
Medical Definition
Autosomal dominant multiple pterygium syndrome is a genetic disorder caused by mutations in the MYH3 gene, leading to abnormal muscle and connective tissue development. Pathologically, it is characterized by the presence of multiple pterygia, joint contractures, and scoliosis. Histological findings may include fibrosis and abnormal muscle fiber arrangement. The condition is classified under genetic disorders with an autosomal dominant inheritance pattern. Epidemiologically, it is considered a rare disease with a prevalence of approximately 1 in 500,000. The disease course can vary, with some individuals experiencing mild symptoms while others have more severe physical limitations.
Autosomal dominant multiple pterygium syndrome Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Pterygium formation manifests as web-like skin folds that occur in areas such as the neck, elbows, and knees. This condition is caused by abnormal connective tissue development due to mutations in the MYH3 gene. Over time, these skin folds may become more pronounced and restrict movement. Daily life can be affected by limited range of motion, and physical therapy may help improve flexibility and function.
Craniofacial anomalies include features such as a cleft palate, micrognathia, and low-set ears. These anomalies arise from disrupted embryonic development of the craniofacial structures due to genetic mutations. As the child grows, these features may become more apparent and may require surgical intervention. They can impact feeding, speech, and hearing, necessitating multidisciplinary care and support.
Skeletal abnormalities often present as scoliosis, joint contractures, and short stature. These arise from improper bone and joint development linked to the MYH3 gene mutations. The severity of these abnormalities can increase with age, potentially leading to significant physical limitations. Management may include orthopedic interventions and regular monitoring to prevent complications.
Common
Respiratory difficulties may present as recurrent respiratory infections or breathing problems. These issues are often due to chest wall abnormalities and reduced lung capacity. Over time, respiratory function may decline, necessitating medical interventions. Daily life can be impacted by fatigue and reduced exercise tolerance, and respiratory therapy may be beneficial.
Hearing loss can be conductive or sensorineural and may present early in life. It is caused by structural anomalies in the ear or nerve pathways. Hearing loss may progress, affecting communication and learning. Early intervention with hearing aids or other assistive devices can improve quality of life.
Congenital heart defects can include conditions such as ventricular septal defects or valve abnormalities. These defects result from improper cardiac development during embryogenesis. The severity of heart defects can vary, and they may require surgical correction. Regular cardiac monitoring and management are essential to prevent complications and support overall health.
Less Common
Genitourinary anomalies may include conditions like cryptorchidism or renal malformations. These arise from abnormal development of the urinary and reproductive systems. Over time, these anomalies can lead to complications such as urinary tract infections or fertility issues. Surgical correction or medical management may be necessary to address these concerns.
Neurological issues can manifest as developmental delays or seizures. These are thought to be linked to structural brain anomalies or disrupted neural pathways. The progression of neurological symptoms can vary, with some individuals experiencing significant challenges. Early intervention with therapies and medications can help manage symptoms and support development.
What Causes Autosomal dominant multiple pterygium syndrome?
Autosomal dominant multiple pterygium syndrome is primarily caused by mutations in the MYH3 gene, which is located on chromosome 17p13.1. The MYH3 gene encodes for embryonic myosin heavy chain 3, a protein crucial for muscle development and function. Mutations in MYH3 lead to structural changes in the myosin protein, impairing its ability to interact with actin filaments. This disruption in protein function affects muscle contraction and cellular movement. The immediate molecular consequence is the accumulation of dysfunctional myosin, which interferes with normal muscle fiber assembly. As a result, there is a cascade of effects leading to impaired muscle development and function. Dysfunctional muscle fibers can trigger an inflammatory response, further exacerbating tissue damage. Neuroinflammation may occur as the body attempts to repair damaged tissues, potentially affecting nerve function. Over time, this can lead to degeneration of muscle tissues and associated structures, such as tendons and ligaments. The specific pattern of symptoms, such as pterygia and joint contractures, arises from the particular muscles and connective tissues affected. Variability in disease severity among patients is likely due to differences in mutation type, genetic background, and environmental factors. Some individuals may have milder forms of the disease due to compensatory mechanisms in muscle development. The immune response may also vary, influencing the degree of inflammation and tissue damage. Additionally, the extent of white matter degeneration can impact neurological symptoms. Overall, the interplay between genetic mutations, cellular dysfunction, and immune response determines the clinical presentation.
How is Autosomal dominant multiple pterygium syndrome Diagnosed?
Typical age of diagnosis: Diagnosis typically occurs in early childhood when characteristic physical features become apparent, often during routine pediatric examinations or when developmental delays are noted.
The clinician looks for distinctive features such as webbing of the neck, elbows, and knees, and other skeletal anomalies. A detailed family history is crucial to identify any hereditary patterns, as the condition is autosomal dominant. Physical examination may reveal joint contractures, scoliosis, and craniofacial dysmorphisms. This step helps to differentiate from other syndromes with overlapping features and directs towards genetic evaluation.
X-rays and MRI are commonly used to assess skeletal abnormalities and joint contractures. Imaging may show vertebral anomalies, fusion of cervical vertebrae, and other skeletal deformities. These findings support the clinical diagnosis and help exclude conditions like arthrogryposis multiplex congenita. Imaging also aids in planning surgical interventions if necessary.
Routine laboratory tests are generally not diagnostic but may include metabolic panels to rule out other conditions. Biomarkers specific to this syndrome are not typically identified in standard tests. Abnormal results might include elevated inflammatory markers if there is associated joint inflammation. These results guide further genetic testing and specialist referrals.
Genetic testing focuses on sequencing the MYH3 gene, where mutations are known to cause the syndrome. Mutations typically involve missense or nonsense changes affecting protein function. Positive results confirm the diagnosis and are crucial for family counseling regarding inheritance patterns. Genetic findings also assist in prenatal diagnosis and risk assessment for family members.
Autosomal dominant multiple pterygium syndrome Treatment Options
NSAIDs are used to manage pain and inflammation associated with joint contractures. They work by inhibiting cyclooxygenase enzymes, reducing prostaglandin synthesis. Commonly used drugs include ibuprofen and naproxen, which have shown efficacy in reducing symptoms. However, long-term use can lead to gastrointestinal and renal side effects. Regular monitoring and dose adjustments are necessary to minimize risks.
Physical therapy involves specific techniques to improve joint mobility and prevent contractures. The therapeutic goal is to maintain functional range of motion and enhance quality of life. Sessions are typically conducted 2-3 times per week, with each session lasting about an hour. Measurable outcomes include improved joint flexibility and reduced pain. Long-term benefits include enhanced mobility and delayed progression of contractures.
Surgery is indicated for severe joint contractures that significantly impair function. The procedure involves releasing or lengthening tendons and soft tissues to improve joint mobility. Expected benefits include increased range of motion and improved daily functioning. Surgical risks include infection, bleeding, and recurrence of contractures. Post-operative care involves intensive physical therapy to maintain surgical gains.
The care team typically includes geneticists, orthopedic surgeons, physical therapists, and psychologists. Interventions focus on comprehensive management of physical and psychosocial needs. Psychosocial support strategies include counseling and support groups for patients and families. Family education is provided on the condition, its progression, and management strategies. Long-term monitoring plans involve regular follow-ups to assess and adjust treatment as needed.
When to See a Doctor for Autosomal dominant multiple pterygium syndrome
- Severe breathing difficulties β this may indicate airway obstruction, which requires immediate medical attention.
- Sudden onset of paralysis β this could be a sign of nerve compression or other serious complications.
- Acute chest pain β this may suggest cardiovascular involvement and needs urgent evaluation.
- Progressive joint stiffness β this could indicate worsening of the condition and may require intervention.
- Increasing difficulty with mobility β this may suggest the need for physical therapy or assistive devices.
- Persistent pain in affected areas β this could indicate complications and should be assessed by a healthcare provider.
- Mild joint discomfort β monitor for changes and manage with over-the-counter pain relief if necessary.
- Occasional skin irritation β keep the area clean and moisturized, and monitor for signs of infection.
Autosomal dominant multiple pterygium syndrome β Frequently Asked Questions
Is this condition hereditary?
Autosomal dominant multiple pterygium syndrome is inherited in an autosomal dominant pattern, meaning one copy of the altered gene in each cell is sufficient to cause the disorder. There is a 50% chance of passing the condition to offspring if one parent is affected. De novo mutations can occur, meaning the mutation can appear for the first time in an individual with no family history. Carrier status is not applicable as the condition is dominant. Genetic counseling is recommended for affected individuals and their families to understand inheritance patterns and risks.
What is the life expectancy for someone with this condition?
Life expectancy can vary depending on the severity and management of symptoms. Early onset with severe manifestations may lead to a reduced lifespan due to complications like respiratory issues. Mortality is often related to complications such as airway obstruction or cardiovascular problems. Effective management and treatment can improve quality of life and potentially extend survival. Realistic expectations should include ongoing medical care and possible interventions to manage symptoms.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves a combination of clinical evaluation, family history, and genetic testing. The time from first symptoms to diagnosis can vary, often depending on the awareness of the condition by healthcare providers. Specialists such as geneticists and orthopedic surgeons are commonly consulted. Delayed diagnosis can occur due to the rarity of the condition and overlapping symptoms with other disorders. Genetic testing confirming mutations in the MYH3 gene is the definitive diagnostic step.
Are there any new treatments or clinical trials available?
Current research is exploring the potential of gene therapy and other novel approaches to treat autosomal dominant multiple pterygium syndrome. ClinicalTrials.gov is a resource for finding ongoing trials and new treatment options. Patients should discuss with their doctors the possibility of participating in clinical trials. Questions to ask include eligibility criteria and potential benefits and risks of participation. New treatments may still be several years away from being widely available.
How does this condition affect daily life and activities?
The condition can significantly impact mobility and self-care, often requiring physical therapy and assistive devices. Educational accommodations may be necessary due to physical limitations. Social and emotional challenges can arise from visible symptoms and functional impairments. The condition can place a considerable burden on families, necessitating support and adaptation. Access to resources such as occupational therapy and support groups can greatly assist in managing daily life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.An autosomal dominant multiple pterygium syndrome.
McKeown CM, Harris R Β· J Med Genet Β· 1988 Β· PMID: 2831369
- 2.Autosomal-Dominant Multiple Pterygium Syndrome Is Caused by Mutations in MYH3.
Chong JX, Burrage LC, Beck AE et al. Β· Am J Hum Genet Β· 2015 Β· PMID: 25957469
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-08